Britain and America have announced a landmark bilateral deal that will maintain zero levies on UK medicine exports entering the US market.
The Terms of the Pact
As part of the deal, the UK has agreed to raise expenditure on drugs through the public health system. This pledge secures that import taxes on these crucial exports will stay at zero for a timeframe of the next three years.
This deal comes after recent statements to hike duties on patented drug products, with figures mentioned as high as double the cost.
"This agreement with the Britain bolsters the global environment for new treatments and brings much-needed fairness to American-British medicine commerce," a release declared.
Trade Impact
Medicines constitute one of the Britain's largest export categories to the America, which is by far the largest market for leading British pharmaceutical firms.
Export figures reveal that in the one-year period leading up to September, the UK shipped drugs worth billions to the US. This value made up nearly one-fifth of total UK exports in that span.
"This deal safeguards employment, stimulates funding and facilitates the UK to emerge as a international leader for medical research," the Business and Trade Secretary stated.
Detailed NHS Changes
The agreement includes several specific pledges from the British government:
- Revised Affordability Limit: The UK will increase the price threshold at which it deems new medicines to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a goal to increase total NHS spending on treatments from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The sum drug companies must return to the NHS to control costs will be limited at fifteen percent. Last year, repayments topped twenty percent.
Industry Background
This agreement takes place against a ongoing dispute between the drug companies and the UK government over medicine costs and regulatory access.
These tensions were heightened by claims that US patients were charged several times more for the identical medicines than consumers in the Britain and the EU.
Over the last 18 months, several large pharmaceutical investments in the UK have been delayed or cancelled, while multi-billion-dollar investments have been announced toward projects in the United States.
A senior figure publicly accepted that the NHS must increase expenditure on drugs, noting that its budget allocation on drugs had decreased as a share of its resources over the last ten years.
